| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2024―Dez―11 |
Тромбоз-ассоциированные и гематологические заболевания в период пандемии COVID-19. |
Н.И. Микуляк, И.Я. Моисеева, И.А. Сорокин, А.А. Михайлис |
| 2 |
[GO] |
2024―Sep―28 |
Clinical and laboratory features of COVID-19-patients in severe and extremely severe condition. |
А.А. Набиева, Д.А. Кудлай, А.Х. Трегубова, Б.А. Бакиров, Д.В. Морозовский, В.В. Ефимова, А.А. Ладутько |
| 3 |
[GO] |
2023―Dez―10 |
Dynamics of MCP-1 and IP-10 level in obese patients under anticoagulant therapy in COVID-19 |
Р.Е. Калинин, И.А. Сучков, А.Б. Агапов, Н.Д. Мжаванадзе, В.О. Поваров, А.А. Никифоров |
| 4 |
[GO] |
2023―Sep―23 |
The role of D-dimer and other coagulation parameters for diagnosing hemostatic disorders in patients with COVID-19 |
Е.А. Бовт, С.С. Шахиджанов, А.Е. Филиппова, Ф.И. Атауллаханов, А.Г. Румянцев |
| 5 |
[GO] |
2023―Jun―29 |
Pluripotent mechanisms for regulation of hemostasis and thrombogenesis in COVID-19 |
Б.И. Кузник, Е.В. Ройтман, Н.Н. Цыбиков, К.Г. Шаповалов, Ю.Н. Смоляков |
| 6 |
[GO] |
2023―Jun―29 |
COVID-19-related thrombosis: new experiences and challenges of thrombotic complications arising from the pandemic |
П.Г. Мадонов, А.П. Момот, Е.В. Ройтман, В.В. Удут |
| 7 |
[GO] |
2023―Mrz―21 |
Optimization of thrombinemia laboratory diagnostics in COVID-19-patients |
Н.А. Воробьева, А.И. Воробьева, А.С. Бартенева |
| 8 |
[GO] |
2023―Mrz―21 |
Genetic predisposition to a vascular catastrophe: does it affect severe COVID-19? |
Т.И. Дутова, И.Н. Банин, И.Э. Сазонов, Е.И. Пелешенко |
| 9 |
[GO] |
2022―Dez―18 |
Acute stroke associated with novel coronavirus infection COVID-19 |
Е.Н. Кабаева, П.Ф. Литвицкий, О.П. Артюков, К.А. Тушова, Н.В. Ноздрюхина, А.В. Ершов |
| 10 |
[GO] |
2022―Dez―18 |
Coagulopathy and risk factors in patients with severe COVID-19 |
Р.Е. Калинин, И.А. Сучков, А.Б. Агапов, Н.Д. Мжаванадзе, Д.А. Максаев, А.А. Чобанян |
| 11 |
[GO] |
2022―Sep―22 |
Features of platelet link of hemostasis in novel coronavirus disease COVID-19. |
Н.В. Изможерова, А.А. Попов, И.П. Антропова, Т.М. Сайфутдинов, Л.И. Кадников, М.А. Шамбатов, et al. (+2) В.Е. Испавский, А.В. Рябинина |
| 12 |
[GO] |
2022―Sep―22 |
Proteinase-activated PAR4 receptors and hemostasis in COVID-19. |
Д.А. Дьяков, О.Е. Акбашева, Л.В. Спирина, И.Ю. Шувалов, А.Е. Кебекбаева, Н.С. Денисов, et al. (+2) В.В. Макова, В.Н. Масунов |
| 13 |
[GO] |
2022―Sep―22 |
Platelets, leukocytes and their ratio as predictors of outcomes in patients with COVID-19. |
Б.И. Кузник, Ю.Н. Смоляков, К.Г. Шаповалов, С.А. Лукьянов, Н.Н. Цыбиков, Е.В. Фефелова, et al. (+3) Л.С. Казанцева, Ю.К. Шаповалов, А.А. Нархинова |
| 14 |
[GO] |
2022―Sep―22 |
Effect of anticoagulant prophylaxis on hemostasis activation in the acute period of coronavirus infection. |
О.Ю. Матвиенко, Л.П. Папаян, Н.Е. Корсакова, О.Г. Головина, А.А. Лернер |
| 15 |
[GO] |
2022―Mrz―26 |
Pathogenetic continuum of coagulopathies and the complexity of their therapy in COVID-19 |
Е.П. Харченко |
| 16 |
[GO] |
2022―Mrz―26 |
Anticoagulant treatment for severe COVID-19 with high bleeding risk. |
В.В. Колесников, Е.В. Ройтман, А.А. Леонов |
| 17 |
[GO] |
2021―Nov―30 |
Changing physicians’ attitudes regarding anticoagulant therapy for novel coronavirus infection in 2021. |
Е.В. Ройтман, С.М. Маркин, П.Ф. Кравцов, К.В. Мазайшвили |
| 18 |
[GO] |
2021―Sep―20 |
Clinical cases of eculizumab use as a part of complex therapy in patients with severe COVID-19. |
Р.А. Майер, Б.А. Бакиров, А.А. Набиева, Д.А. Кудлай |
| 19 |
[GO] |
2021―Sep―20 |
Hemorrhagic complications of а novel coronavirus infection: actual clinical problem. |
И.Б. Симарова, С.Н. Переходов, А.Ю. Буланов |
| 20 |
[GO] |
2021―Jul―01 |
Dermatological manifestations in novel coronavirus infection COVID-19 |
А.А. Хрянин, В.Г. Стуров, А.П. Надеев, В.К. Бочарова |
| 21 |
[GO] |
2021―Mai―17 |
The realities of the anticoagulant therapy using in COVID-19. |
Е.В. Ройтман, Т.В. Вавилова, С.М. Маркин, П.Ф. Кравцов, К.В. Мазайшвили |
| 22 |
[GO] |
2021―Mai―17 |
Pathogenetic mechanisms of hypofibrinogenemia in COVID-19 |
С.Е. Работинский, Е.Л. Буланова |
| 23 |
[GO] |
2021―Mai―17 |
Therapeutic targets in COVID-19 coagulopathy |
М.В. Кондашевская |
| 24 |
[GO] |
2021―Mai―17 |
Hemodynamics and heart rate variability in seriously ill COVID-19 patients at the height of the disease and in the process of rehabilitation |
Б.И. Кузник, Ю.Н. Смоляков, Ю.К. Шаповалов, Н.А. Нольфин, Д.С. Партс |
| 25 |
[GO] |
2021―Feb―01 |
The nature of eculizumab monoclonal antibody and its potential against coronavirus infection COVID-19 |
Д.А. Кудлай, Б.А. Бакиров, В.Н. Павлов |
| 26 |
[GO] |
2021―Feb―01 |
Low molecular weight heparins dosing and anti-factor Xa activity in patients with novel coronavirus infection COVID-19. |
Е.В. Ройтман, А.Ю. Буланов, В.М. Печенников |
| 27 |
[GO] |
2021―Feb―01 |
The complexity of coagulopathy pathogenesis in COVID-19. |
Е.П. Харченко |
| 28 |
[GO] |
2021―Feb―01 |
Microparticles of blood cells in patients with COVID-19 as a marker of hemostasis activation |
О.В. Сироткина, А.И. Ермаков, Л.Б. Гайковая, Д.А. Кудлай, Т.В. Вавилова |
| 29 |
[GO] |
2021―Feb―01 |
Coagulopathy in COVID-19 infection |
С.И. Кузнецов, Е.А. Шестаков, Е.Б. Жибурт |
| 30 |
[GO] |
2021―Feb―01 |
The opportunity of dipyridamole using for nonspecific primary prophylaxis against the COVID-19 infection in healthcare staff |
И.В. Куртов, Ю.О. Берман, Н.А. Никулина, Ю.В. Кузнецова, И.Л. Давыдкин |
| 31 |
[GO] |
2021―Feb―01 |
Anticoagulant management for pregnant women with coronavirus infection |
И.А. Лапина, Ю.Э. Доброхотова, В.В. Таранов, Т.Г. Чирвон |
| 32 |
[GO] |
2021―Feb―01 |
Plasma hemostasis in patients with coronavirus infection caused by SARS-CoV-2. |
О.Ю. Матвиенко, Н.Е. Корсакова, А.А. Лернер, Т.Н. Шведова, Л.П. Папаян |
| 33 |
[GO] |
2021―Feb―01 |
New coronavirus infection, hemostasis and heparin dosing problems: It is important to say now |
А.Ю. Буланов, Е.В. Ройтман |
| 34 |
[GO] |
2021―Feb―01 |
Heparin inhalation in patients with new coronavirus infection (review) |
Н.А. Воробьева, Е.В. Ройтман, Е.Ю. Мельничук |
